ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BI 3812465

A development code. Also written as “Low dose BI 3812465”, “Medium dose BI 3812465” and “High dose BI 3812465”.

Its studies are mostly in Macular Edema, led by Boehringer Ingelheim.

Furthest: phase 2, since Apr 22, 20261 company-led study, 1 open or runningNext primary completion: Mar 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim11 open or runningphase 2since Apr 22, 2026Apr 22, 2026Mar 23, 2027phase 2 · NCT07553429

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2026First study: phase 2 study in Diabetic Macular EdemaFirst studyNCT07553429 · 49 planned · United States, Puerto Rico

Ahead

  1. Mar 23, 2027Primary completion: phase 2 study in Diabetic Macular EdemaNCT07553429

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553429Diabetic Macular Edema · United States, Puerto Rico2RecruitingMar 23, 202749

How it is read

Names in the registry

  • “Low dose BI 3812465”, 1 entry
  • “Medium dose BI 3812465”, 1 entry
  • “High dose BI 3812465”, 1 entry

Codes read as this program: BI3812465.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.